NCT02091388: Bioavailability of LY03004 and Risperdal® Consta® |
|
|
| Completed | 1 | 108 | US | LY03004, Risperdal® Consta® | Luye Pharma Group Ltd. | Schizophrenia, Schizoaffective Disorder | 01/15 | 01/15 | | |
NCT02186769: An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 1 | 16 | US | Risperdal® Consta®, LY03004 | Luye Pharma Group Ltd. | Schizophrenia, Schizoaffective Disorder | 04/15 | 04/15 | | |
NCT02411526: Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia |
|
|
| Completed | 1 | 60 | US | ZX003 (Risperidone-SABER®), Relday, Risperdal Consta, risperidone, Oral Risperidone, risperdal | Zogenix, Inc. | Schizophrenia, Schizoaffective Disorder | 09/15 | 09/15 | | |
